Eli Lilly Close to Acquiring Cancer Biotech Kelonia Therapeutics in Imminent Deal

Pharmaceutical giant Eli Lilly is nearing a deal to acquire cancer-focused biotechnology company Kelonia Therapeutics, with an agreement potentially coming as soon as Monday, according to sources familiar with the matter.

The acquisition would mark another significant move by Eli Lilly to expand its oncology portfolio, as the Indianapolis-based drugmaker continues to deploy capital following the blockbuster success of its diabetes and weight-loss treatments.

Kelonia Therapeutics specializes in cancer immunotherapy, developing next-generation treatments designed to harness the body's immune system to target and destroy tumor cells. The biotech has drawn considerable attention from larger pharmaceutical players seeking to bolster their pipelines with innovative oncology assets.

The financial terms of the deal have not yet been disclosed, and representatives for both companies declined to comment. However, sources indicate that negotiations are in advanced stages and a formal announcement could come within days.

The potential acquisition reflects a broader trend of large-cap pharmaceutical companies aggressively pursuing biotech targets in the oncology space, where demand for novel therapies remains high and regulatory pathways have become increasingly favorable.

Eli Lilly has been on an acquisitions spree in recent years, investing heavily to diversify beyond its core metabolic disease franchise. A successful deal for Kelonia would signal the company's deepening commitment to becoming a major force in cancer treatment.